Advances in MET tyrosine kinase inhibitors in gastric cancer

Ítems similars

• The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
  per: Tejas Patil, MD, et al.
  Publicat: (2024-02-01)
• Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
  per: Keunchil Park, MD, PhD, et al.
  Publicat: (2021-09-01)
• Advances in MET tyrosine kinase inhibitors in gastric cancer
  per: Yifan Zhang, et al.
  Publicat: (2024-06-01)
• Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
  per: Ryota Nakamura, MD, et al.
  Publicat: (2023-06-01)
• Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy
  per: Priyanka S. Waghmare, et al.
  Publicat: (2024-07-01)